Menu
Search
|

Menu

Close
X

CTI Biopharma Corp CTIC.OQ (NASDAQ Stock Exchange Capital Market)

1.68 USD
-0.00 (-0.00%)
As of 3:59 PM EST
chart
Previous Close 1.68
Open 1.71
Volume 32,609
3m Avg Volume 105,860
Today’s High 1.71
Today’s Low 1.66
52 Week High 5.36
52 Week Low 1.65
Shares Outstanding (mil) 57.99
Market Capitalization (mil) 97.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
12
FY17
25
FY16
57
FY15
16
EPS (USD)
FY18
-0.533
FY17
-1.285
FY16
-1.709
FY15
-6.618
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
7.94
15.43
Price to Book (MRQ)
vs sector
1.71
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
25.20
14.84
LT Debt to Equity (MRQ)
vs sector
18.33
11.13
Return on Investment (TTM)
vs sector
-75.73
12.77
Return on Equity (TTM)
vs sector
-98.74
14.47

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3101 Western Ave Ste 800
SEATTLE   WA   98121-3017

Phone: +1206.2827100

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

SPONSORED STORIES